|Venture Round, 5/2009 ||$13M|
|Series E, 1/2010 |
Generali Financial Holding
|Grant, 9/2013 ||$4M|
|Venture Round, 2/2014 ||$7.5M|
|Venture Round, 3/2014 ||$392k|
|Debt, 3/2009 ||$2.56M|
GlobeImmune, Inc. operates as a biopharmaceutical company. It engages in developing and manufacturing Tarmogens, a targeted molecular immunotherapy for the treatment of cancer and infectious diseases. Its products include GI-3000, a Tarmogen for epidermal growth factor receptor over expressing tumors; GI-4000, a Tarmogen for mutated-Ras mediated cancers; GI-5005, a Tarmogen for chronic hepatitis C infection; GI-8000, a Tarmogen for influenza; and GI-10000 Targeted Ablation of Mutational Escape, a novel use of the Tarmogen platform that eliminates or prevents the emergence of mutated escape variants in patients receiving antiviral or targeted cancer therapies. GlobeImmune, Inc. was founded in 1995 as Ceres Pharmaceuticals, Inc. The company is based in Louisville, Colorado.